CLINICAL PROJECTS

CELL THERAPIES

​

We are a clinical-stage immune-based cell therapy company committed to the discovery, development and commercialization of novel or highly differentiated cell therapies to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. Our mission is to bring transformational medicines to patients through innovation.

 

We are envisaging vast commercial opportunities for immuno-oncology and autoimmune cell based therapies in China and Southeast Asia part of the world. We were founded to capture the opportunities presented by the confluence of two major developments: the emergence of an attractive and growing cell based market in China Southeast Asia, and revolutionary scientific breakthroughs in cancer and autoimmune disease medicines.

 

To achieve our mission and capitalize on these commercial opportunities, we have developed a business model built on two pillars. The first is a fast-to-market China approach, and the second a fast-to-PoC (proof of concept) global approach. Reflecting these two approaches, we have established a China Portfolio and a Global Portfolio of novel or highly differentiated clinical and preclinical cell based assets in the most exciting therapeutic areas of immuno-oncology and immuno-inflammation. Through our internal research and development efforts, and in-licensing arrangements with global pharmaceutical and biotech companies, we have built an innovative pipeline of more than nine assets in clinical and preclinical stages of development. We are currently running three Phase 2 or 3 clinical trials in the US and Southeast Asia, and a further five trials, mostly Phase 1, in China, Russia, Canada and Southeast Asia.

 

We have strong conviction that we are uniquely positioned as a Singapore-based global player, with a presence in China, Southeast Asia, Canada and the US, to tap into these vast commercial opportunities. Since its founding in 2016, FEGO Biotech Group which has spun off FEGO Cell Therapies, is set to become one of the top innovative biotech companies in Asia. Our research and development capabilities encompass discovery, translational medicine, pre-clinical development and clinical development, as well as business development functions. These integrated capabilities are strengthened by our deep understanding of Asia’s cell therapies regulatory framework combined with our direct access to extensive preclinical and clinical trial resources in China and Southeast Asia. FEGO Cell Therapies is now at a critical juncture to transition from a clinical-stage biotech company into a fully integrated end-to-end global biopharmaceutical company in the next few years.

 

FEGO Cell Therapies competitive pipeline and dynamic business strategy makes it perfectly positioned to capitalize on unique business conditions in China and Southeast Asia: a growing talent pool of professionals with both global and local R&D expertise; a critical mass of cell based therapies services and programs operating according to global standards; a rapidly improving regulatory and drug-innovation environment; and large capital resources. These factors, coupled with the huge market potential of China’s and Southeast Asia’s vast patient population and growing global reach, give us remarkable power and speed in developing innovative medicines.

​

 

BIOSIMILARS

​

FEGO Biotech main focus is in immunology therapy and managing autoimmune diseases. We are a “clinical-stage” biotech company, with a strong focus on Biosimilars. This is not just a business revenue area but importantly an “aid” helping human beings to have a healthier lifespan. Biosimilars are generic versions of existing Biologics of innovator-drugs upon patents expiry and we hope to hold one of the largest biosimilars portfolios in Singapore in monoclonal antibodies and other biologics for virology, oncology, immunology and other therapeutic cures.

 

We are well positioned to offer these highly innovative drugs or medicines at cheaper costs. The demand for biosimilars is set to grow as the reference patents expire on leading biologics and more patients demand lower priced drugs. FEGO Biotech is partnering with several international clinical-stage companies for their own researched biosimilars with cutting edge platform technologies. With long term collaboration in joint research and market distribution for market in ASEAN, FEGO aims to set up a fill-finish plant unit in Singapore for innovative biologics and Biosimilars.  We are constantly in discussion with Chinese pharmaceutical firms as well.

 

Biosimilars in the pipeline

​

• The two leading candidates – FEGDP1 AND FEGDP2.

 

• FEGDP1 – It is a biosimilar version of Adalimumab, – a TNF Inhibitor intended to treat patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis and plaque psoriasis. FEGO comes with its own brand and we are working closely with established research group on this as we try to launch it in 2022.

 

• FEGDP2 – It is a biosimilar version of Trastuzumab- the best available medicine for breast cancer with HER-2 receptor positive. FEGO’s biosimilar version will work on itself or in combination with chemotherapy products.

 

• FEGDP3 – Denosumab injection is in a class of medications called RANK ligand inhibitors. It works to prevent bone loss by blocking a certain receptor in the body to decrease bone breakdown. It works to treat GCTB by blocking a certain receptor in the tumor cells which slows the tumor growth. It works to treat high calcium levels by decreasing bone breakdown as the breakdown of bones releases calcium

 

• FEGDP4 – Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A)

 

• FEGDP5 –Ranibizumab is a recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.

 

• FEGDP6 – Liraglutide is an anti-diabetic medication used to treat type 2 diabetes, obesity, and chronic weight management.

 

• FEGDP7 – Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system

​